China Universal Asset Management Co. Ltd. lifted its holdings in shares of argenx SE (NASDAQ:ARGX - Free Report) by 10.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,837 shares of the company's stock after buying an additional 663 shares during the quarter. China Universal Asset Management Co. Ltd.'s holdings in argenx were worth $4,205,000 at the end of the most recent quarter.
Other institutional investors also recently modified their holdings of the company. Cromwell Holdings LLC lifted its stake in shares of argenx by 73.3% during the 3rd quarter. Cromwell Holdings LLC now owns 156 shares of the company's stock valued at $85,000 after buying an additional 66 shares in the last quarter. GAMMA Investing LLC lifted its stake in argenx by 47.5% in the 3rd quarter. GAMMA Investing LLC now owns 174 shares of the company's stock worth $94,000 after purchasing an additional 56 shares in the last quarter. SG Americas Securities LLC lifted its stake in argenx by 6.2% in the 4th quarter. SG Americas Securities LLC now owns 358 shares of the company's stock worth $220,000 after purchasing an additional 21 shares in the last quarter. Fulton Bank N.A. purchased a new stake in shares of argenx during the 4th quarter valued at $226,000. Finally, Blue Trust Inc. raised its position in shares of argenx by 413.9% during the 3rd quarter. Blue Trust Inc. now owns 370 shares of the company's stock valued at $201,000 after buying an additional 298 shares in the last quarter. 60.32% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
ARGX has been the topic of several research reports. Wedbush restated an "outperform" rating and set a $655.00 price objective on shares of argenx in a research report on Tuesday, December 3rd. Guggenheim increased their target price on shares of argenx from $585.00 to $665.00 and gave the company a "buy" rating in a report on Friday, November 1st. Evercore ISI increased their target price on shares of argenx from $675.00 to $706.00 and gave the company an "outperform" rating in a report on Thursday, November 21st. Wells Fargo & Company increased their target price on shares of argenx from $639.00 to $723.00 and gave the company an "overweight" rating in a report on Thursday, December 19th. Finally, Truist Financial reaffirmed a "buy" rating and set a $700.00 target price (up previously from $660.00) on shares of argenx in a report on Tuesday, January 14th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $658.39.
Get Our Latest Analysis on argenx
argenx Stock Up 2.7 %
argenx stock traded up $17.26 during trading hours on Wednesday, hitting $668.56. The stock had a trading volume of 245,523 shares, compared to its average volume of 279,630. The stock has a market capitalization of $40.62 billion, a P/E ratio of -758.28 and a beta of 0.58. argenx SE has a 12-month low of $349.86 and a 12-month high of $678.21. The stock's 50-day moving average price is $634.50 and its 200-day moving average price is $573.66.
argenx Company Profile
(
Free Report)
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.
Read More
Before you consider argenx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and argenx wasn't on the list.
While argenx currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
